Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells

• Published in: Journal of the American Chemical Society Vol. 146; no. 13; pp. 8877 - 8886
• Main Authors: Ball, Andrew T., Mohammed, Soran, Doigneaux, Cyrielle, Gardner, Reece M., Easton, James W., Turner, Steven, Essex, Jonathan W., Pairaudeau, Garry, Tavassoli, Ali
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 03.04.2024; Amer Chemical Soc
• Subjects: Cell Hypoxia; Chemistry; Chemistry, Multidisciplinary; Humans; Hypoxia; Hypoxia-Inducible Factor 1 - metabolism; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism; Neoplasms - drug therapy; Oxygen - metabolism; Peptides, Cyclic - metabolism; Peptides, Cyclic - pharmacology; Physical Sciences; Science & Technology; Signal Transduction; ACTIVATION; SOLID TUMORS; TRANSCRIPTION; BIOLOGY; GENE-EXPRESSION; HIF2-ALPHA; FACTOR-I; HIF-1-ALPHA; TISSUES; BINDING
• ISSN: 0002-7863; 1520-5126
• DOI: 10.1021/jacs.3c10508

Hypoxia inducible factor (HIF) is a heterodimeric transcription factor composed of an oxygen-regulated α subunit and a constitutively expressed β subunit that serves as the master regulator of the cellular response to low oxygen concentrations. The HIF transcription factor senses and responds to hypoxia by significantly altering transcription and reprogramming cells to enable adaptation to a hypoxic microenvironment. Given the central role played by HIF in the survival and growth of tumors in hypoxia, inhibition of this transcription factor serves as a potential therapeutic approach for treating a variety of cancers. Here, we report the identification, optimization, and characterization of a series of cyclic peptides that disrupt the function of HIF-1 and HIF-2 transcription factors by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β. These compounds are shown to bind to HIF-α and disrupt the protein–protein interaction between the α and β subunits of the transcription factor, resulting in disruption of hypoxia-response signaling by our lead molecule in several cancer cell lines.